Ascendis Pharma A/S’s (ASND) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $220.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($3.49) EPS and FY2026 earnings at $2.43 EPS.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a research note on Monday, October 13th. Finally, Stifel Nicolaus lifted their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $256.60.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $209.55 on Tuesday. The stock has a fifty day moving average of $202.89 and a two-hundred day moving average of $185.83. The company has a market capitalization of $12.93 billion, a PE ratio of -40.61 and a beta of 0.44. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $223.18.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $26,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at $39,000. First Horizon Advisors Inc. purchased a new stake in Ascendis Pharma A/S during the 2nd quarter worth $41,000. Jones Financial Companies Lllp increased its holdings in Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.